Recent Updates
Recently added Catalysts
NERV Positive Sentiment Score: 70/100

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Wednesday, March 1, 2023 1 min read
Key Takeaway: Minerva Neurosciences, Inc. plans to announce its fiscal year 2022 financial results and business updates on March 8, 2023. A webcast will be held at 8:30 a.m. Eastern Time that day for a detailed discussion. The company is focused on developing therapies for central nervous system disorders, including its compounds for schizophrenia and Parkinson's disease. The archived webinar will be accessible on the company's website shortly after the live event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Minerva Neurosciences is set to release important financial results and business updates.
  • The upcoming report may provide insights into the company's development efforts in CNS disorders.
  • The company has a clear focus on transforming therapeutic options for CNS disease patients.

Full Press Release Details

BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial results and business updates on Wednesday, March 8, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.
The live conference call may be accessed here and on the Company’s website under Events and Presentations.
The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.
For more information:
CFO, Minerva Neurosciences
info@minervaneurosciences.com
Principal, Shik Communications LLC
helen@shikcommunications.com

Tags

Minerva Neurosciences

Frequently Asked Questions

When will Minerva Neurosciences release financial results?

Minerva Neurosciences will release its financial results on March 8, 2023.

What time is the conference call on March 8, 2023?

The conference call is scheduled for 8:30 a.m. Eastern Time.

How can I access the conference call?

You can access the conference call via the Company's website under Events and Presentations.

What products is Minerva Neurosciences developing?

Minerva is developing roluperidone for schizophrenia and MIN-301 for Parkinson’s disease.

How long will the archived webcast be available?

The archived webcast will be available for 90 days after the event.

Tags: NERV Viatris Investor Conferences Healthcare Minerva Neurosciences CNS disorders financial results business updates
Last updated: Mar 1, 2023